FAS and steatosis: Using steatosis score as the readout, they scanned a panel of anti-NAFLD drugs (positive on animal models), and found inhibitors of ACC, FAS and DGAT2, a FXR agonist, as well as recombinant hFGF19 could efficiently alleviate the steatosis in FFA models and APOB−/−or MTTP−/− models.